Critical Therapeutics, Phase III Trial of Zileuton in Patients with Acute Exacerbations of COPD

Oct. 15, 2007- Critical Therapeutics (Nasdaq: CRTX) announced the start of patient enrollment in the LEUKO study, a randomized, double-blind, placebo-controlled efficacy trial to examine the effects of ZYFLO(R) (zileuton tablets) used in the treatment of adults with Chronic Obstructive Pulmonary Disease (COPD). The purpose of this trial is to examine the effectiveness of ZYFLO at reducing the length of a hospital stay for adults who are hospitalized for a COPD exacerbation, or a worsening of their COPD symptoms... Critical Therapeutics' Press Release-